Company news

Cabaletta Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

October 31, 2021

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021

October 14, 2021

Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference

September 27, 2021

Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

September 6, 2021

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

August 17, 2021

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

June 27, 2021

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

May 2, 2021

Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

May 2, 2021

Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

March 15, 2021

Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris

December 7, 2020

Cabaletta Bio to Participate in Upcoming December Investor Conferences

November 22, 2020

Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update

November 9, 2020

Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris

August 24, 2020

Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies

July 6, 2020

Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania

May 27, 2020

Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform

May 17, 2020

Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

May 5, 2020

Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

March 29, 2020

FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris

January 28, 2020

Cabaletta Bio Announces Pricing of Initial Public Offering

October 24, 2019

← Newer news releases

Calls

Decks

The 5 newest of 50 decks. Every deck is listed under its year.